Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 12/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15646695 | 0.81 | KMT2A (0.40) | CYP3A4CYP2C9CYP2C19KMT2ALMNA | |
| SCHEMBL15646494 | 0.80 | NAMPT (0.55) | NAMPTCYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL15647056 | 0.80 | NAMPT (0.58) | NAMPTCYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL4539298 | 0.78 | NAMPT (0.52) | NAMPTCYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL12693115 | 0.77 | NAMPT (0.50) | NAMPTCYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL15646599 | 0.77 | NAMPT (0.52) | NAMPTCYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL15645673 | 0.76 | HTR2C (0.53) | NAMPTCYP3A4CYP2C9CYP2C19KDM4E | |
| SCHEMBL15646864 | 0.76 | HTR2C (0.53) | NAMPTCYP3A4CYP2C9CYP2C19KDM4E | |
| SCHEMBL15645922 | 0.76 | HTR2C (0.53) | NAMPTCYP3A4CYP2C9CYP2C19KDM4E | |
| SCHEMBL15645840 | 0.76 | NAMPT (0.54) | NAMPTCYP3A4CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1S, KCNN4 | NAMPT 4652/4885CYP3A4 322/4885CYP2C9 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.